Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

Gian Luca Di Tanna (), Michael Urbich, Heidi S. Wirtz, Barbara Potrata, Marieke Heisen, Craig Bennison, John Brazier and Gary Globe
Additional contact information
Gian Luca Di Tanna: University of New South Wales
Michael Urbich: Amgen (Europe) GmbH, Global Value & Access, Modeling Center of Excellence
Heidi S. Wirtz: Amgen Inc, Global Health Economics
Barbara Potrata: Pharmerit - an OPEN Health company
Marieke Heisen: Pharmerit - an OPEN Health company
Craig Bennison: Pharmerit - an OPEN Health company
John Brazier: Health Economics and Decision Science, University of Sheffield
Gary Globe: Amgen Inc, Global Health Economics

PharmacoEconomics, 2021, vol. 39, issue 2, No 6, 229 pages

Abstract: Abstract Background and Objectives New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic literature review was conducted to identify and summarize heart failure utility values for use in economic evaluations. Methods Databases were searched for articles published until June 2019 that reported health utility values for patients with heart failure. Publications were reviewed with specific attention to study design; reported values were categorized according to the health states, ‘chronic heart failure’, ‘hospitalized’, and ‘other acute heart failure’. Interquartile limits (25th percentile ‘Q1’, 75th percentile ‘Q3’) were calculated for health states and heart failure subgroups where there were sufficient data. Results The systematic literature review identified 161 publications based on data from 142 studies. Utility values for chronic heart failure were reported by 128 publications; 39 publications published values for hospitalized and three for other acute heart failure. There was substantial heterogeneity in the specifics of the study populations, methods of elicitation, and summary statistics, which is reflected in the wide range of utility values reported. EQ-5D was the most used instrument; the interquartile limit for mean EQ-5D values for chronic heart failure was 0.64–0.72. Conclusions There is a wealth of published utility values for heart failure to support economic evaluations. Data are heterogenous owing to specificities of the study population and methodology of utility value elicitation and analysis. Choice of value(s) to support economic models must be carefully justified to ensure a robust economic analysis.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-020-00984-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:2:d:10.1007_s40273-020-00984-6

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-020-00984-6

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().